Mylona Ioanna, Tsinopoulos Ioannis
2nd Department of Ophthalmology, Aristotle University of Thessaloniki, 564 29 Thessaloniki, Greece.
Pharmaceuticals (Basel). 2020 Dec 8;13(12):448. doi: 10.3390/ph13120448.
Cataract surgery is the commonest ophthalmic surgery worldwide. The replacement of the diseased lens with a synthetic one (intraocular lens-IOL) remains the treatment of choice, despite its potential complications that include infection, inflammation and posterior capsule opacification. The potential for drug delivery via the IOL has been researched extensively over a period of twenty-five years, yet there is very limited progress in transferring the findings from research to everyday practice. The objective of this review is to assess the progress made in the field of IOL lens modifications and drug delivery systems over the past five years. Thirty-six studies that were conducted during the past five years were identified and deemed suitable for inclusion. They were grouped in three broad categories, studies that described new methods for loading a drug onto the IOL, assessment of the effects of drugs that were loaded to the IOL and studies that assessed the effects of non-pharmaceutical modifications of IOLs. While considerable progress is continually being made with regard to methods and materials, there is still little capitalization upon these research studies, with no commercially available IOL-based drug delivery system being available. Close cooperation between researchers in basic sciences (chemistry, physics, materials science and pharmacy), clinical researchers, IOL manufacturers and the pharmaceutical industry is an important prerequisite for further development.
白内障手术是全球最常见的眼科手术。用人工晶状体(IOL)替换病变晶状体仍然是首选治疗方法,尽管其潜在并发症包括感染、炎症和后囊混浊。二十五年来,通过人工晶状体进行药物递送的潜力得到了广泛研究,但将研究结果转化为日常实践的进展非常有限。本综述的目的是评估过去五年在人工晶状体修饰和药物递送系统领域取得的进展。确定了过去五年进行的三十六项研究,并认为适合纳入。它们分为三大类:描述将药物加载到人工晶状体上的新方法的研究、评估加载到人工晶状体上的药物效果的研究以及评估人工晶状体非药物修饰效果的研究。虽然在方法和材料方面不断取得相当大的进展,但这些研究成果的利用仍然很少,目前还没有基于人工晶状体的商业化药物递送系统。基础科学(化学、物理学、材料科学和药学)研究人员、临床研究人员、人工晶状体制造商和制药行业之间的密切合作是进一步发展的重要前提。